Hiromichi Matsuoka1,2,3, Satoru Iwase4, Tempei Miyaji5, Takashi Kawaguchi6, Keisuke Ariyoshi7, Shunsuke Oyamada7, Eriko Satomi8, Hiroto Ishiki8, Hideaki Hasuo9, Hiroko Sakuma9, Akihiro Tokoro10, Yoshinobu Matsuda10, Kazuki Tahara11, Hiroyuki Otani12, Yoichi Ohtake13, Hiroaki Tsukuura14, Yoshihisa Matsumoto15, Yoshikazu Hasegawa16, Yuki Kataoka17, Masatomo Otsuka18, Kiyohiro Sakai19,20, Miki Nakura19, Tatsuya Morita21, Takuhiro Yamaguchi22, Atsuko Koyama19,20. 1. Department of Psychosomatic Medicine, Kindai University Faculty of Medicine, Osaka, Japan. matsuoka_h@med.kindai.ac.jp. 2. Palliative Care Center, Kindai University Faculty of Medicine, Osaka, Japan. matsuoka_h@med.kindai.ac.jp. 3. Faculty of Health, University of Technology Sydney, Sydney, Australia. matsuoka_h@med.kindai.ac.jp. 4. Department of Palliative Medicine, University of Saitama Medical University, Saitama, Japan. 5. Department of Clinical Trial Data Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 6. Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. 7. Japanese Organization for Research and Treatment of Cancer (JORTC), JORTC Data Center, Tokyo, Japan. 8. Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan. 9. Department of Psychosomatic Internal Medicine, Kansai Medical University, Osaka, Japan. 10. Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan. 11. Yamanobe General Hospital Internal medicine, Nara, Japan. 12. Department of Palliative Medicine, National Kyushu Cancer Center, Fukuoka, Japan. 13. Itami Seifu Hospital Internal medicine, Hyogo, Japan. 14. Nagoya University Hospital, Aichi, Japan. 15. Department of Palliative Medicine, National Cancer Center East, Kashiwa, Japan. 16. Department of Medical Oncology, Izumi City General Hospital, Izumi, Japan. 17. Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan. 18. Department of Palliative Medicine, Kindai University Nara Hospital, Nara, Japan. 19. Department of Psychosomatic Medicine, Kindai University Faculty of Medicine, Osaka, Japan. 20. Palliative Care Center, Kindai University Faculty of Medicine, Osaka, Japan. 21. Palliative and Supportive Care Division, Seirei Mikatahara General Hospital, Hamamatsu, Japan. 22. Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Abstract
PURPOSE:Duloxetine has some effect against cancer neuropathic pain (CNP); however, predictors of duloxetine response are unclear. This study sought to identify predictors of duloxetine response in patients with CNP. METHODS:Patients (N = 70) with CNP unresponsive to or intolerant of opioid-pregabalin combination therapy, with a brief pain inventory-short form (BPI-SF) Item 5 score (average pain) ≥ 4, and with a total hospital anxiety and depression scale score < 20, were randomized to a duloxetine or a placebo group. Multiple linear regression analysis was conducted to identify predictors of duloxetine response as a secondary analysis with the change in the average pain score on day 10 from day 0 as the dependent variable, and the following five covariates; baseline (day 0) average pain score, baseline opioid dose, continuation/discontinuation of pregabalin, and items 20 and 21 score of the short-form McGill painquestionnaire 2 (SF-MPQ-2) as independent variables. RESULTS: Of the four domains (continuous pain, intermittent pain, neuropathic pain, and affective descriptors) score of SF-MPQ-2 on day 0, significant differences were observed in the neuropathic pain domain (p = 0.040) in change on the average pain between day 10 and day 0 in the duloxetine group. Multiple linear regression analysis revealed that patients with a high score for SF-MPQ-2 Item 21 (tingling pain) on day 0 had a significantly greater change in average pain between day 10 and day 0 (p = 0.046). CONCLUSION: Patients with a high score for SF-MPQ-2 Item 21 might benefit more from duloxetine.
RCT Entities:
PURPOSE:Duloxetine has some effect against cancer neuropathic pain (CNP); however, predictors of duloxetine response are unclear. This study sought to identify predictors of duloxetine response in patients with CNP. METHODS:Patients (N = 70) with CNP unresponsive to or intolerant of opioid-pregabalin combination therapy, with a brief pain inventory-short form (BPI-SF) Item 5 score (average pain) ≥ 4, and with a total hospital anxiety and depression scale score < 20, were randomized to a duloxetine or a placebo group. Multiple linear regression analysis was conducted to identify predictors of duloxetine response as a secondary analysis with the change in the average pain score on day 10 from day 0 as the dependent variable, and the following five covariates; baseline (day 0) average pain score, baseline opioid dose, continuation/discontinuation of pregabalin, and items 20 and 21 score of the short-form McGill pain questionnaire 2 (SF-MPQ-2) as independent variables. RESULTS: Of the four domains (continuous pain, intermittent pain, neuropathic pain, and affective descriptors) score of SF-MPQ-2 on day 0, significant differences were observed in the neuropathic pain domain (p = 0.040) in change on the average pain between day 10 and day 0 in the duloxetine group. Multiple linear regression analysis revealed that patients with a high score for SF-MPQ-2 Item 21 (tingling pain) on day 0 had a significantly greater change in average pain between day 10 and day 0 (p = 0.046). CONCLUSION:Patients with a high score for SF-MPQ-2 Item 21 might benefit more from duloxetine.
Authors: Christian Geber; Markus Breimhorst; Berenike Burbach; Christina Egenolf; Bernhard Baier; Marcel Fechir; Juergen Koerber; Rolf-Detlef Treede; Thomas Vogt; Frank Birklein Journal: Pain Date: 2013-08-30 Impact factor: 6.961
Authors: Thomas M Atkinson; Tito R Mendoza; Laura Sit; Steven Passik; Howard I Scher; Charles Cleeland; Ethan Basch Journal: Pain Med Date: 2010-01-15 Impact factor: 3.750
Authors: R-D Treede; T S Jensen; J N Campbell; G Cruccu; J O Dostrovsky; J W Griffin; P Hansson; R Hughes; T Nurmikko; J Serra Journal: Neurology Date: 2007-11-14 Impact factor: 9.910
Authors: Christopher Robinson; Suhani Dalal; Ahish Chitneni; Anand Patil; Amnon A Berger; Syed Mahmood; Vwaire Orhurhu; Alan D Kaye; Jamal Hasoon Journal: Health Psychol Res Date: 2022-05-30